降糖药物治疗与恶性肿瘤  

Antidiabetic therapies and cancer

作　　者：杜瑞[1] 陆洁莉[1] 毕宇芳[1] 宁光[1] 

机构地区：[1]上海交通大学医学院附属瑞金医院内分泌代谢病科,上海市内分泌代谢病研究所,上海市内分泌代谢病临床医学中心,200025

出　　处：《中华内分泌代谢杂志》2016年第3期253-256,共4页Chinese Journal of Endocrinology and Metabolism

基　　金：国家自然科学基金项目（81370960）

摘　　要：近年来不断有流行病学研究证实2型糖尿病与恶性肿瘤风险增加相关，糖尿病本身的病理变化导致的代谢异常在其中发挥重要作用。同时，越来越多的研究证实降糖药物与恶性肿瘤相关．其中较为重要的有噻唑烷二酮类药物降低肝癌和乳腺癌风险，二甲双胍降低所有恶性肿瘤的风险，一代、二代磺脲类促泌剂、胰岛素及胰岛素类似物可能升高恶性肿瘤风险。深入分析目前降糖药物与肿瘤相关性的研究可以为后续临床决策的选择和抗肿瘤治疗提供指导。Recently, evidence from epidemiological studies suggest that type 2 diabetes is associated with the increase of cancer risk, the metabolic disorders caused by intrinsic pathological changes of diabetes play important roles. In addition, more and more studies demonstrated the correlation between antidiabetic drugs and cancer, e.g. metformin may decrease the risk of cancer, thiatholidinediones possiblely reduce the risk of liver and breast cancer, while first and second generation of sulfonylureas, insulin and insulin analogue therapies probably increase malignancies＇ risk. The thorough investigation into the prevalent studies focusing on the association between antidiabetic drugs and cancer can provide better suggestions for clinical decision and anti-cancer therapies.

关 键 词：糖尿病 2型 降糖药物 恶性肿瘤 

分 类 号：R587.1[医药卫生—内分泌] R73-3[医药卫生—内科学]